– Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab –
SAN DIEGO and SUZHOU, China, Dec 7 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from December 8 to 11, 2021. Both posters are available in the Publications section of the company’s website at www.adagene.com.
- UN Envoy Urges More Support For Syria As 400,000 Syrian Refugees Return From Lebanon
- Civil Defence In Gaza Warns Of “Humanitarian Disaster” Due To Rainwater
- Iraqi Militia Claimed Two Drone Attacks On Southern Israel
- Zionist Israel Hit Beirut With New Strikes As Weekend Death Toll Reaches 29
- Jordan Says Shooting Incident Against Police Patrol “Terrorist Attack”
- Lee Hsien Loong Supports Lawrence Wong To Lead Singapore’s Ruling Party
- 18 Killed, Over 30 Injured In Armed Clashes In NW Pakistan
- Iraq Warns Of Possible Israeli Attacks In Letters To UN
- India’s Main Ruling Party BJP-Led Alliance Wins Key State Maharashtra
- Authorities To Deploy Over 10,000 Additional Paramilitary Troopers In India’s Manipur